Supplementary Material for: Advances in Futile Reperfusion following Endovascular Treatment in Acute Ischemic Stroke due to Large Vessel Occlusion

<b><i>Background:</i></b> Futile reperfusion (FR) is becoming an urgent issue for acute ischemic stroke patients who underwent endovascular treatment (EVT). Although the recanalization rate has improved after EVT, it is far from translating to increased tissue reperfusion and functional independence. <b><i>Summary:</i></b> Many underlying mechanisms including the “no-reflow” phenomenon, poor collateral flow, venous dysfunction, and inflammation were proposed, but the pathophysiology of FR is still unclear. Clinically, reliable predictors are still yet to be identified, and ongoing trials on shortening the time delay and cytoprotection may provide novel ideas for interventions of FR. <b><i>Key Messages:</i></b> This review will summarize the latest advances in FR and hopefully shed light on potential interventions.

**背景：** 无效再灌注（Futile Reperfusion, FR）正成为接受血管内治疗（Endovascular Treatment, EVT）的急性缺血性脑卒中患者面临的迫切临床问题。尽管血管内治疗后血管再通率已有所提升，但这远未转化为组织再灌注水平的改善与患者功能独立性的提高。
**概述：** 尽管已提出包括无复流现象（no-reflow phenomenon）、侧支循环血流不佳、静脉功能障碍及炎症反应在内的多种潜在机制，但无效再灌注的病理生理学机制仍未明确。临床层面，目前仍未确定可靠的预测因子；而当前正在开展的关于缩短时间延迟与细胞保护的相关试验，或许可为无效再灌注的干预策略提供新思路。
**核心要点：** 本综述将总结无效再灌注领域的最新研究进展，以期为潜在干预手段的探索提供指引。